Cosmo Pharmaceuticals N.V
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesa… Read more
Cosmo Pharmaceuticals N.V (CMOPF) - Net Assets
Latest net assets as of June 2025: $466.98 Million USD
Based on the latest financial reports, Cosmo Pharmaceuticals N.V (CMOPF) has net assets worth $466.98 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($610.33 Million) and total liabilities ($143.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $466.98 Million |
| % of Total Assets | 76.51% |
| Annual Growth Rate | N/A |
| 5-Year Change | 26.23% |
| 10-Year Change | 25.13% |
| Growth Volatility | 200.29 |
Cosmo Pharmaceuticals N.V - Net Assets Trend (2004–2024)
This chart illustrates how Cosmo Pharmaceuticals N.V's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cosmo Pharmaceuticals N.V (2004–2024)
The table below shows the annual net assets of Cosmo Pharmaceuticals N.V from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $505.09 Million | +17.73% |
| 2023-12-31 | $429.04 Million | -7.49% |
| 2022-12-31 | $463.79 Million | -9.54% |
| 2021-12-31 | $512.68 Million | +28.13% |
| 2020-12-31 | $400.12 Million | +1.62% |
| 2019-12-31 | $393.73 Million | -11.49% |
| 2018-12-31 | $444.85 Million | -5.37% |
| 2017-12-31 | $470.12 Million | +13.13% |
| 2016-12-31 | $415.56 Million | +2.95% |
| 2015-12-31 | $403.65 Million | +165.05% |
| 2014-12-31 | $152.29 Million | -30.83% |
| 2013-12-31 | $220.16 Million | +76.69% |
| 2012-12-31 | $124.60 Million | +96.43% |
| 2011-12-31 | $63.43 Million | +8.68% |
| 2010-12-31 | $58.37 Million | -2.39% |
| 2009-12-31 | $59.80 Million | +38.30% |
| 2008-12-31 | $43.24 Million | +23.01% |
| 2007-12-31 | $35.15 Million | +557.69% |
| 2006-12-31 | $5.34 Million | +746.91% |
| 2005-12-31 | $631.00K | +171.70% |
| 2004-12-31 | $-880.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cosmo Pharmaceuticals N.V's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 32696900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $323.06 Million | 64.83% |
| Common Stock | $4.56 Million | 0.92% |
| Other Comprehensive Income | $-19.28 Million | -3.87% |
| Other Components | $189.99 Million | 38.12% |
| Total Equity | $498.33 Million | 100.00% |
Cosmo Pharmaceuticals N.V Competitors by Market Cap
The table below lists competitors of Cosmo Pharmaceuticals N.V ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hunan Jiudian Pharmaceutical Co Ltd
SHE:300705
|
$529.98 Million |
|
Zhejiang Dayuan Pumps Ind Co
SHG:603757
|
$530.18 Million |
|
TES Co. Ltd
KQ:095610
|
$530.25 Million |
|
Ovzon AB
ST:OVZON
|
$530.40 Million |
|
ARGAN EO 2
F:871
|
$529.83 Million |
|
Shanxi Blue Flame Holding Co Ltd
SHE:000968
|
$529.77 Million |
|
Gravita India Limited
NSE:GRAVITA
|
$529.44 Million |
|
Zhejiang Sunflower Light Energy
SHE:300111
|
$529.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cosmo Pharmaceuticals N.V's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 422,160,000 to 498,330,000, a change of 76,170,000 (18.0%).
- Net income of 133,236,000 contributed positively to equity growth.
- Dividend payments of 32,094,000 reduced retained earnings.
- Share repurchases of 5,931,000 reduced equity.
- New share issuances of 3,377,000 increased equity.
- Other comprehensive income increased equity by 1,897,000.
- Other factors decreased equity by 24,315,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $133.24 Million | +26.74% |
| Dividends Paid | $32.09 Million | -6.44% |
| Share Repurchases | $5.93 Million | -1.19% |
| Share Issuances | $3.38 Million | +0.68% |
| Other Comprehensive Income | $1.90 Million | +0.38% |
| Other Changes | $-24.32 Million | -4.88% |
| Total Change | $- | 18.04% |
Book Value vs Market Value Analysis
This analysis compares Cosmo Pharmaceuticals N.V's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.07x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $-0.38 | $62.80 | x |
| 2005-12-31 | $0.25 | $62.80 | x |
| 2006-12-31 | $0.61 | $62.80 | x |
| 2007-12-31 | $2.63 | $62.80 | x |
| 2008-12-31 | $3.12 | $62.80 | x |
| 2009-12-31 | $4.03 | $62.80 | x |
| 2010-12-31 | $3.92 | $62.80 | x |
| 2011-12-31 | $4.38 | $62.80 | x |
| 2012-12-31 | $9.03 | $62.80 | x |
| 2013-12-31 | $15.39 | $62.80 | x |
| 2014-12-31 | $10.44 | $62.80 | x |
| 2015-12-31 | $28.03 | $62.80 | x |
| 2016-12-31 | $28.85 | $62.80 | x |
| 2017-12-31 | $31.74 | $62.80 | x |
| 2018-12-31 | $29.57 | $62.80 | x |
| 2019-12-31 | $26.91 | $62.80 | x |
| 2020-12-31 | $27.65 | $62.80 | x |
| 2021-12-31 | $29.89 | $62.80 | x |
| 2022-12-31 | $27.82 | $62.80 | x |
| 2023-12-31 | $26.21 | $62.80 | x |
| 2024-12-31 | $30.35 | $62.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cosmo Pharmaceuticals N.V utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 26.74%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 49.94%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 1.30x
- Recent ROE (26.74%) is above the historical average (16.80%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | -19.92% | 0.47x | 0.00x | $-2.11 Million |
| 2005 | 132.81% | 5.40% | 0.55x | 44.71x | $774.90K |
| 2006 | -2.56% | -0.90% | 0.64x | 4.42x | $-671.40K |
| 2007 | 0.33% | 0.53% | 0.46x | 1.34x | $-3.40 Million |
| 2008 | 21.74% | 27.51% | 0.59x | 1.34x | $5.08 Million |
| 2009 | 6.77% | 15.18% | 0.37x | 1.20x | $-1.93 Million |
| 2010 | 6.21% | 11.25% | 0.35x | 1.58x | $-2.20 Million |
| 2011 | 12.04% | 22.70% | 0.43x | 1.23x | $1.29 Million |
| 2012 | 15.53% | 32.46% | 0.39x | 1.22x | $6.88 Million |
| 2013 | 31.22% | 121.94% | 0.23x | 1.10x | $46.72 Million |
| 2014 | 48.15% | 92.12% | 0.35x | 1.48x | $58.09 Million |
| 2015 | 61.49% | 409.51% | 0.14x | 1.08x | $207.83 Million |
| 2016 | 4.65% | 28.58% | 0.15x | 1.07x | $-22.21 Million |
| 2017 | -6.90% | -48.25% | 0.14x | 1.06x | $-79.46 Million |
| 2018 | -4.07% | -27.52% | 0.10x | 1.41x | $-62.43 Million |
| 2019 | -6.22% | -39.19% | 0.11x | 1.49x | $-63.87 Million |
| 2020 | -1.97% | -12.96% | 0.10x | 1.49x | $-47.91 Million |
| 2021 | 4.29% | 33.30% | 0.08x | 1.59x | $-28.86 Million |
| 2022 | 3.77% | 16.87% | 0.13x | 1.66x | $-28.47 Million |
| 2023 | -1.17% | -5.32% | 0.17x | 1.31x | $-47.15 Million |
| 2024 | 26.74% | 49.94% | 0.41x | 1.30x | $83.40 Million |
Industry Comparison
This section compares Cosmo Pharmaceuticals N.V's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $342,562,344,444
- Average return on equity (ROE) among peers: 17.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cosmo Pharmaceuticals N.V (CMOPF) | $466.98 Million | 0.00% | 0.31x | $529.97 Million |
| AbbVie Inc (ABBV) | $13.10 Billion | 35.24% | 10.50x | $390.88 Billion |
| Astellas Pharma Inc (ALPMF) | $1.06 Trillion | 7.80% | 0.36x | $16.93 Billion |
| Amgen Inc (AMGN) | $20.39 Billion | 20.58% | 0.79x | $196.91 Billion |
| Amarin Corporation PLC (AMRN) | $28.90 Million | 14.19% | 0.23x | $303.32 Million |
| AstraZeneca PLC (AZN) | $48.72 Billion | 21.05% | 1.34x | $296.35 Billion |
| Bayer AG (BAYZF) | $31.90 Billion | 14.21% | 1.58x | $21.61 Billion |
| Biogen Inc (BIIB) | $325.20 Million | 9.96% | 0.10x | $26.81 Billion |
| Bristol-Myers Squibb Company (BMY) | $5.08 Billion | 14.69% | 0.67x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $1.90 Trillion | 20.37% | 0.16x | $28.30 Billion |